Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Comparator B Clear all
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

NCT04394351
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year to 11 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Lu AG22515 in Healthy Adults

NCT05136053
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AG22515, Placebo, Immune System Activator
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
19 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MET233 in Individuals With Obesity or Overweight

NCT07022977
View directory record Official record
Conditions
Obesity and Overweight
Interventions
MET233, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 28, 2026, 5:23 PM EDT
Recruiting Phase 2 Interventional

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT03587701
View directory record Official record
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 5:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

NCT06381466
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
AZD0233, AZD0233 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT00645177
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABT-869, paclitaxel, Placebo for ABT-869
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Francisco, California • Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Urolithin A Supplementation in Middle-aged Adults With Obesity

NCT05921266
View directory record Official record
Conditions
Obesity, Vascular Dementia, Cognitive Impairment
Interventions
Urolithin A, Placebo
Dietary Supplement · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
40 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 28, 2026, 5:23 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

NCT07145229
View directory record Official record
Conditions
Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Interventions
ABP-745 Dose A, ABP-745 Dose B, Colchicine, Placebo
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Peoria, Arizona • La Mesa, California • Norcross, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 28, 2026, 5:23 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06154837
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK3862995B, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
10
States / cities
Yuma, Arizona • Hialeah, Florida • Orange City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 28, 2026, 5:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza

NCT02014649
View directory record Official record
Conditions
Influenza
Interventions
20 mg laninamivir octanoate, Placebo, 40 mg laninamivir octanoate
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
5 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

NCT00843635
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Tadalafil, Placebo
Drug · Other
Lead sponsor
Donald T. Weed
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

NCT04033926
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
KZR-616, Placebo
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Beverly Hills, California • Orange, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough Corrected QT Interval Trial

NCT02073084
View directory record Official record
Conditions
Dyslipidemia
Interventions
K-877 Low Dose, Moxifloxacin, Placebo, K-877 High Dose
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

NCT00831506
View directory record Official record
Conditions
Alzheimer Disease, Huntington Disease
Interventions
digoxin, dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2009 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

NCT00095121
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Placebo, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Anaheim, California • La Verne, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 28, 2026, 5:23 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 28, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 28, 2026, 5:23 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Andecaliximab, Placebo
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
2 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

NCT02341638
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Placebo, Aspirin, Itraconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Cypress, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

NCT00630812
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled mannitol, Placebo comparator
Drug
Lead sponsor
Syntara
Industry
Eligibility
6 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
28
States / cities
Tucson, Arizona • Hartford, Connecticut • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers

NCT00656357
View directory record Official record
Conditions
Cocaine Dependence
Interventions
SYN117 Placebo, SYN117 80 mg, SYN117 160 mg, Cocaine 10mg, Cocaine 20mg, Cocaine 40mg, Saline
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

Use of Ketorolac in Management of Post-Operative Pain After Heart Surgery

NCT00161577
View directory record Official record
Conditions
Pain Management Following Cardiopulmonary Bypass Surgery
Interventions
Ketorolac, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2009 · Synced Sep 28, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants

NCT07566130
View directory record Official record
Conditions
Healthy Volunteers
Interventions
nacresertib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 28, 2026, 5:23 PM EDT